Supernus Pharmaceuticals Debt to Equity Ratio 2011-2024 | SUPN

Current and historical debt to equity ratio values for Supernus Pharmaceuticals (SUPN) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Supernus Pharmaceuticals debt/equity for the three months ending September 30, 2024 was 0.00.
Supernus Pharmaceuticals Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2024-09-30 $0.34B $1.01B 0.33
2024-06-30 $0.36B $0.96B 0.37
2024-03-31 $0.38B $0.93B 0.40
2023-12-31 $0.36B $0.92B 0.39
2023-09-30 $0.37B $0.91B 0.41
2023-06-30 $0.37B $0.92B 0.41
2023-03-31 $0.88B $0.91B 0.96
2022-12-31 $0.82B $0.89B 0.92
2022-09-30 $0.84B $0.85B 0.99
2022-06-30 $0.85B $0.84B 1.01
2022-03-31 $0.81B $0.83B 0.98
2021-12-31 $0.87B $0.82B 1.07
2021-09-30 $0.75B $0.81B 0.92
2021-06-30 $0.79B $0.79B 1.00
2021-03-31 $0.75B $0.75B 1.00
2020-12-31 $0.76B $0.75B 1.02
2020-09-30 $0.80B $0.71B 1.13
2020-06-30 $0.83B $0.67B 1.24
2020-03-31 $0.58B $0.61B 0.94
2019-12-31 $0.57B $0.60B 0.95
2019-09-30 $0.55B $0.56B 0.99
2019-06-30 $0.54B $0.52B 1.03
2019-03-31 $0.55B $0.48B 1.14
2018-12-31 $0.53B $0.45B 1.16
2018-09-30 $0.50B $0.42B 1.19
2018-06-30 $0.46B $0.39B 1.18
2018-03-31 $0.47B $0.35B 1.35
2017-12-31 $0.16B $0.27B 0.59
2017-09-30 $0.13B $0.25B 0.53
2017-06-30 $0.12B $0.23B 0.51
2017-03-31 $0.12B $0.21B 0.56
2016-12-31 $0.12B $0.19B 0.61
2016-09-30 $0.11B $0.17B 0.65
2016-06-30 $0.11B $0.11B 0.98
2016-03-31 $0.10B $0.10B 1.00
2015-12-31 $0.10B $0.09B 1.14
2015-09-30 $0.09B $0.08B 1.12
2015-06-30 $0.08B $0.07B 1.14
2015-03-31 $0.08B $0.06B 1.19
2014-12-31 $0.10B $0.04B 2.36
2014-09-30 $0.09B $0.04B 2.49
2014-06-30 $0.06B $0.03B 1.82
2014-03-31 $0.07B $0.03B 2.36
2013-12-31 $0.08B $0.03B 2.32
2013-09-30 $0.11B $0.01B 8.94
2013-06-30 $0.10B $0.04B 2.68
2013-03-31 $0.04B $0.04B 0.92
2012-12-31 $0.04B $0.06B 0.63
2012-09-30 $0.04B $0.03B 1.72
2012-06-30 $0.04B $0.04B 1.11
2012-03-31 $0.04B $0.00B 156.67
2011-12-31 $0.04B $0.01B 4.69
2011-09-30 $0.00B $0.00B 0.00
2011-06-30 $0.00B $0.00B 0.00
2011-03-31 $0.00B $0.00B 0.00
2010-12-31 $0.00B $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $2.000B $0.608B
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.395B 6.36
Dr Reddy's Laboratories (RDY) India $11.853B 22.68
BridgeBio Pharma (BBIO) United States $4.426B 0.00
Bausch Health Cos (BHC) Canada $2.931B 2.13
Amphastar Pharmaceuticals (AMPH) United States $2.186B 13.14
Taysha Gene Therapies (TSHA) United States $0.506B 35.29
Personalis (PSNL) United States $0.245B 0.00
Assembly Biosciences (ASMB) United States $0.096B 0.00
Sol-Gel Technologies (SLGL) Israel $0.015B 0.00
Evoke Pharma (EVOK) United States $0.006B 0.00
Teligent (TLGT) United States $0.000B 0.00